Lee L Rubin Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Lee Rubin CRIS stock SEC Form 4 insiders trading

Lee has made over 10 trades of the Curis Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Lee exercised 10,000 units of CRIS stock worth 15,000$ on 1 June 2004.

The largest trade Lee's ever made was exercising 45,000 units of Curis Inc stock on 13 January 2004 worth over 63,000$. On average, Lee trades about 9,538 units every 12 days since 2003.

You can see the complete history of Lee Rubin stock trades at the bottom of the page.

What's Lee Rubin's mailing address?

Lee's mailing address filed with the SEC is , , , , .

Insiders trading at Curis Inc

Over the last 24 years, insiders at Curis Inc have traded over 10,321,234$ worth of Curis Inc stock and bought 10,678,594 units worth 25,596,192$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Discovery Technologies Ltd ...、James R Mcnab. On average, Curis Inc executives and independent directors trade stock every 62 days with the average trade being worth of 811,553$. The most recent stock trade was executed by James E Dentzer on 27 January 2022, trading 5,500 units of CRIS stock currently worth 17,160$.

What does Curis Inc do?

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl

Complete history of Lee Rubin stock trades at Curis Inc

Curis Inc executives and stock owners

Curis Inc executives and other stock owners filed with the SEC include:

• James Dentzer,
  President, Chief Executive Officer, Director
• James E. Dentzer,
  Pres, CEO & Director
• Robert Martell,
  Head - Research and Development
• William Steinkrauss,
  Chief Financial Officer
• Dr. Robert E. Martell,
  Head of R&D
• William E. Steinkrauss,
  Chief Financial Officer
• Martyn Greenacre,
  Independent Chairman of the Board
• Kenneth Kaitin,
  Independent Director
• Marc Rubin,
  Independent Director
• Lori Kunkel,
  Independent Director
• Elif McDonald,
  VP of Investor Relations & Corp. Communications
• Dr. Reinhard Wilhelm von Roemeling,
  Sr. VP of Clinical Devel.
• Mark W. Noel,
  VP of Technology Management & Intellectual Property
• John Hohneker,
  Director
• James R Mcnab,
  Director
• David Tuck,
  Chief Medical Officer
• Ali Ph.D. Fattaey,
  President & COO
• Kenneth Pienta,
  Director
• Discovery Technologies Ltd ...,
  
• Douglas Melton,
  Director
• Lee L Rubin,
  Senior Vice President,Research
• Mary Elizabeth Potthoff,
  Vice President,General Counsel
• Mani Mohindru,
  Sr. VP, Corp. Strategy & IR
• Christopher U Missling,
  Sr. Vice President, Finance
• Ruth B Kunath,
  Director
• Jaye Viner,
  Chief Medical Officer
• Michael Gray,
  Chief Financial Officer
• James R Tobin,
  Director
• Mark Noel,
  Vice President, Tech. Manage.
• Maurizio Voi,
  Chief Medical Officer
• Joseph Md Phd Davie,
  Director
• Susan B Bayh,
  Director
• Changgeng Qian,
  VP, Research & Preclinical Dev
• Capital Management, Llcra C...,
  
• Partners L P/Ilbiotechnolog...,
  
• Stephen Carter,
  Director
• Mitchell Keegan,
  Vice-President
• Joseph M Davie,
  Director
• Daniel R Passeri,
  President and CEO
• Anne Elizabeth Borgman,
  Director
• Diantha Duvall,
  CFO
• Jonathan B. Zung,
  CDO